ABSTRACT OBJECTIVES This study sought to test the hypothesis that end-systolic volume (ESV), as a marker of severity of left ventricular (LV) remodeling, influences the relationship between myocardial viability and survival in patients with coronary artery disease and LV systolic dysfunction.
D
espite advances in diagnosis and treatment, heart failure remains a substantial cause of death and disability (1, 2) , driven importantly by the causal role of coronary artery disease (CAD) in the development of left ventricular (LV) dysfunction (3) . LV systolic dysfunction in the setting of CAD is not always an irreversible process because LV function may improve substantially with beta-blocker therapy, cardiac resynchronization, and revascularization (3) (4) (5) (6) (7) . LV function is most likely to improve with medical, device, or surgical therapies in patients with viable myocardium identified using noninvasive imaging (4, (8) (9) (10) (11) (12) (13) (14) .
Many previous studies, primarily retrospective and performed before the advent of betablockers for LV systolic dysfunction, suggested that myocardial viability also identified patients in whom survival is enhanced with revascularization compared with medical management (8, 15, 16) . In contradistinc- (18) (19) (20) (21) . This theory is plausible but has not been tested prospectively with random allocation of treatment strategies. The current study investigated the impact of LV remodeling on the relationship between myocardial viability, treatment with revascularization versus medical management, and survival in patients enrolled in the STICH trial.
METHODS
PATIENT ENROLLMENT. Design and enrollment criteria for the STICH study and STICH viability substudy have been reported in detail (17, 22, 23) . The STICH study is a multicenter, nonblinded, randomized trial funded by the National Heart, Lung, and Blood Institute (NHLBI). The study of revascularization versus medical therapy was conducted at 99 sites in 22 countries. Patients with angiographic documentation of CAD amenable to surgical revascularization and LV ejection fraction (EF) #35% were eligible for enrollment. Exclusion criteria included left main coronary stenosis >50%, cardiogenic shock, myocardial infarction within 3 months, and need for aortic valve surgery. All participants provided written informed consent. Patients were randomized to receive medical therapy alone or medical therapy plus CABG. A "risk at randomization" score was calculated for each patient using a statistical model derived in an independent dataset from multiple variables with known power to predict 5-year risk of death without CABG (24) . Medical therapy was excellent, with $90% of patients receiving statins, beta-blockers, and either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at 1 year and 88% receiving aspirin ($92% received either aspirin or warfarin) (23) . LV FUNCTION AND ESVs. LVEF and ESV were measured by the independent investigators from core laboratories blinded to treatment allocation. As previously described (25) , the best available method (based on study quality using a pre-determined hierarchical algorithm) was used to measure LVEF and volumes. The end-systolic volume index (ESVI) was computed by dividing ESV by body surface area.
PATIENT FOLLOW-UP. After trial enrollment, patients were followed every 4 months for the first year and every 6 months thereafter (17, 23) . The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular mortality and allcause mortality plus cardiovascular hospitalizations.
All endpoints were adjudicated by an independent clinical events committee (22) .
Baseline clinical characteristics of patients were descriptively summarized using means and SDs, unless otherwise specified. Group characteristics at baseline were compared using the and per protocol (28) . Finally, Cox model analyses were performed treating viability status and ESVI as continuous rather than binary variables.
RESULTS
Among the 601 patients undergoing viability testing, Table 1 , and characteristics of patients without viable myocardium are presented in Table 2 . Among patients with myocardial viability, those with ESVI >84 ml/m Figure 3A , and rates across the continuum of ESVI are shown in Figure 3B . Specifically, patients with greater 
DISCUSSION
The current report extends the analysis of the prospective STICH myocardial viability study (17) studied patients with mean LVEF of 29% and observed Values are mean AE SD or n (%). *The RAR score ranges from 1 to 32, with higher numbers indicating a higher predicted rate of death. Among patients receiving medical therapy, a score of 1 predicts a rate of 18% and a score of 32 predicts a rate of 99% over 5 years.
Abbreviations as in Table 1 . viability (10) (11) (12) . Although patients in the STICH trial had lower mean LVEF than patients with myocardial viability treated medically in prior reports (9, (15) (16) (17) , patients with viable myocardium randomized to medical therapy in STICH had substantially lower annual mortality rates than patients with viability treated medically in the previous studies.
This appears to reflect the adherence to guidelinedriven medical therapy in the majority of patients in this prospective trial (29) .
When myocardial viability was assessed as a continuous variable in the current analysis (Figure 3) , 
